Format

Send to

Choose Destination
J Antimicrob Chemother. 2015 Jan;70(1):14-22. doi: 10.1093/jac/dku355. Epub 2014 Sep 8.

Antifungal drugs during pregnancy: an updated review.

Author information

1
Infectious Diseases Department, Université Paris Descartes, Sorbonne Paris Cité, Centre d'Infectiologie Necker-Pasteur, Hôpital Necker-Enfants Malades, Paris, France.
2
Pharmacology Department, Université Paris Descartes, Sorbonne Paris Cité, Inserm U1129, Hôpital Européen Georges-Pompidou, Paris, France.
3
Wayne State University, Detroit, MI, USA.
4
Infectious Diseases Department, Université Paris Descartes, Sorbonne Paris Cité, Centre d'Infectiologie Necker-Pasteur, Hôpital Necker-Enfants Malades, Paris, France caroline.charlier@nck.aphp.fr.

Abstract

Antifungal prescription remains a challenge in pregnant women because of uncertainties regarding fetal toxicity and altered maternal pharmacokinetic parameters that may affect efficacy or increase maternal and fetal toxicity. We present updated data reviewing the available knowledge and current recommendations regarding antifungal prescription in pregnancy. Amphotericin B remains the first-choice parenteral drug in spite of its well-established toxicity. Topical drugs are used throughout pregnancy because of limited absorption. Recent data have clarified the teratogenic effect of high-dose fluconazole during the first trimester and provided reassuring cumulative data regarding its use at a single low dose in this key period. Recent data have also provided additional safety data on itraconazole and lipidic derivatives of amphotericin B. Regarding newer antifungal drugs, including posaconazole and echinocandins, clinical data are critically needed before considering prescription in pregnancy.

KEYWORDS:

antifungal therapy; fetus; fungal infections; placenta

PMID:
25204341
DOI:
10.1093/jac/dku355
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center